UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Sep

    01

    UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

    Read More Share:linkedin| twitter| email

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    Read More Share:linkedin| twitter| email

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    Read More Share:linkedin| twitter| email

    Jan

    21

    Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

    Read More Share:linkedin| twitter| email

    Nov

    19

    Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)